The Turkish Competition Board (“the Board”) announced its final decision regarding the investigation into Novartis Saglık Gida ve Tarim Urunleri San. ve Tic. A.S. (“Novartis”) and Roche Mustahzarlari San. A.S. (“Roche”) on 22 January, 2021. 

The Board had initiated an in-depth investigation into two pharmaceutical companies, Novartis and Roche, due to their activities that sought to increase and expand the usage of Lucentis, which is the most expensive of the companies' two drugs designated to treat eye diseases. In its investigation, the Board evaluated whether Roche and Novartis had violated Article 4 of Law No: 4054 on the Protection of Competition that prohibits restrictive agreements among competitors. 

In its meeting held on 21 January, 2021, the Board finalized the investigation and unanimously decided that Roche and Novartis had violated Article 4 of the Law. No: 4054. As a result of their findings, the Board imposed turnover-based monetary fines, amounting to TRY 165,464,716 for Roche and TRY 112,972,552 for Novartis, in its decision numbered 21-04/52-21.

The Board will publish the reasoning for its decision at a later date

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.